Nubeqa (darolutamide) is a prescription oral, non-steroidal androgen receptor inhibitor (ARi) used to treat adults with non-metastatic or metastatic castration-resistant and hormone-sensitive prostate cancers by blocking testosterone from feeding cancer cells, often combined with androgen deprivation therapy (ADT).

NUBEQA is the go-to ARI that delivers survival without compromise so that patients can have the best chance to fight for their life and live beyond their prostate cancer.